Table 2. Odds ratios in univariate logistic regression on the probability to be in MR4 nine months after start of nilotinib therapy.
| Patient cohorts, number of patients (n) | PTP | Odds ratio | Lower 95% confidence limit for odds ratio | Upper 95% confidence limit for odds ratio | P value likelihood ratio test |
|---|---|---|---|---|---|
| n = 66 | PTPN13 | 1.045 | 1.009 | 1.092 | 0.0122 |
| PTPRA | 1.275 | 1.073 | 1.561 | 0.0047 | |
| PTPRC | 1.015 | 1.005 | 1.028 | 0.0024 | |
| PTPRG | 1.046 | 1.013 | 1.088 | 0.0039 | |
| PTPRM | 1.019 | 1.004 | 1.038 | 0.0154 | |
| n = 54 | PTPN13 | 1.040 | 0.995 | 1.093 | 0.0834 |
| PTPRA | 1.287 | 1.056 | 1.628 | 0.0112 | |
| PTPRC | 1.013 | 1.001 | 1.027 | 0.0389 | |
| PTPRG | 1.059 | 1.015 | 1.116 | 0.0064 | |
| PTPRM | 1.012 | 0.995 | 1.031 | 0.1748 | |
| n = 35 | PTPN13 | 1.039 | 0.990 | 1.103 | 0.1242 |
| PTPRA | 1.344 | 1.060 | 1.826 | 0.0123 | |
| PTPRC | 1.014 | 1.000 | 1.031 | 0.0430 | |
| PTPRG | 1.087 | 1.026 | 1.175 | 0.0023 | |
| PTPRM | 1.032 | 1.005 | 1.069 | 0.0168 |
PTPs analyzed in cell based assays are highlighted. For cohort details see legend Figure 1.